SCHEDULE 13G/A: Biotechnology Value Fund Group Discloses 9.99% Passive Stake in TScan Therapeutics

A group of investment entities associated with Biotechnology Value Fund (BVF), led by Mark N. Lampert, has disclosed a combined 9.99% beneficial ownership stake in TScan Therapeutics, Inc., primarily through common stock and pre-funded warrants.

Summary

• The filing is an Amendment No. 2 to Schedule 13G, indicating a passive investment by the reporting persons.
• As of March 31, 2025, the aggregate beneficial ownership by the reporting group, including Biotechnology Value Fund L.P., BVF I GP LLC, Biotechnology Value Fund II L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, is 5,263,541 shares.
• This aggregate ownership represents 9.99% of TScan Therapeutics, Inc.'s outstanding Voting Common Stock.
• The percentage is calculated based on 52,314,039 shares outstanding as of February 28, 2025, plus 374,067 shares issuable upon the exercise of certain pre-funded warrants held by the reporting persons.
• The reporting persons hold pre-funded warrants exercisable for an aggregate of 12,060,526 shares, but an ownership limitation (Pre-Funded Warrants Blocker) restricts exercise to 9.99% of outstanding shares, limiting current exercisable warrants to 374,067 shares.
• Specifically, BVF beneficially owned 3,351,425 shares (6.4%), BVF2 beneficially owned 1,505,307 shares (2.9%), and Trading Fund OS beneficially owned 306,903 shares (0.6%).
• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, indicating a neutral sentiment. While a large investor's stake can be seen positively, the filing itself is purely informational without expressing explicit positive or negative views on the company's performance or outlook.

Positives

• A significant stake (9.99%) held by a specialized biotechnology investment fund, Biotechnology Value Fund, may signal confidence in TScan Therapeutics' long-term prospects.
• The passive nature of the investment, as stated in the filing, suggests the fund is not seeking to disrupt current management or strategy, which can provide stability.

Risks

• The Pre-Funded Warrants Blocker limits the immediate exercise of a large portion of the warrants (12,060,526 total warrants vs. 374,067 currently exercisable due to the 9.99% ownership cap), meaning the full potential ownership from these warrants is not immediately realized.

Future Outlook

This Schedule 13G filing is a disclosure of current ownership and does not provide forward-looking statements or guidance from TScan Therapeutics or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

TScan Therapeutics operates in the biotechnology sector, a field characterized by high research and development costs, long development cycles, and significant regulatory hurdles. The investment by a specialized biotechnology fund like BVF indicates continued investor interest in the sector, particularly in companies like TScan that are developing novel therapies.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a prominent biotech investor may influence investor perception and potentially provide a degree of stability or confidence in the stock.
• Management: The passive nature of the investment indicates that the investor is not seeking to influence or change the company's control or operations, allowing management to continue its current strategic path.

Key Dates

Keywords

TScan Therapeutics, Biotechnology Value Fund, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Passive Investment, Institutional Investor, Biotech, TSCAN